ClinicalTrials.Veeva

Menu

Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant Chemotherapy

Sun Yat-sen University logo

Sun Yat-sen University

Status and phase

Unknown
Phase 3

Conditions

Gastric Cancer

Treatments

Dietary Supplement: NutrenOpimum

Study type

Interventional

Funder types

Other

Identifiers

NCT03654534
SYSUCCGPS3

Details and patient eligibility

About

Background: It is known that postoperative malnutrition remains inevitable for gastric cancer patients with adjuvant chemotherapy, which could have prejudicial influence on the compliance of subsequent adjuvant chemotherapy and survival of the patients. A multi-institutional prospective phase 2 study had demonstrated the efficacy of oral nutritional supplements (ONS) for gastric cancer patients undergoing gastrectomy. However, previous studies did not focus the gastric cancer patients with adjuvant chemotherapy. Thus, it is unknown whether the ONS could benefit the gastric cancer patients with adjuvant chemotherapy. A multicenter, phase 3 randomised controlled trial was conducted to compare the ONS with standard diet for postoperative gastric cancer patients with adjuvant chemotherapy. Patients and method: In this study, pathological confirmed stage II-III or T1N1M0 gastric cancer patients who are supposed to receive adjuvant chemotherapy, aged from 18 to 75 years, with body mass index (BMI) from 18.5 to 28.0 kg/m2, and with Eastern Cooperative Oncology Group performance status ≤2, are randomized 1:1 to receive oral administration of NutrenOpimum (Nestle Suisse S.A.), a liquid enteral nutritional food for special medical purpose (FSMP), or standard diet. NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively. The primary end point was postoperative malnutrition, as defined as ratio of the weight loss at 3 months postoperatively to the days 7 postoperatively body weight (body weight loss ratio) higher than 10%; body weight loss ratio at 1, 3, 6 months. Secondary end points were chemotherapy withdrawal, time to adjuvant chemotherapy failure, period of adjuvant chemotherapy, quality of life, grade 3/4 neutropenia, thrombocytopenia, anemia, and severe side effects on digestive tract. Final study analysis will be conducted after the last patient's enrollment.

Enrollment

374 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. be proven to be primary adenocarcinoma of gastric cancer and pathological confirmed stage II-III or T1N1M0
  2. age: 18-75 years
  3. Eastern Cooperative Oncology Group performance status: 0~2
  4. body mass index: 18.5-28.0kg/m2
  5. able to ingest semiliquid diet
  6. without other malignancies with exception of the cured cervical carcinoma in situ and basal cell carcinoma
  7. anticipated overall survival time ≥ 6 months
  8. anticipated period of adjuvant chemotherapy ≥ 3
  9. without severe mental disorder
  10. without severe digestive disease
  11. without Acquired Immune Deficiency Syndrome or diabetes mellitus
  12. without communication barrier
  13. informed consensus of patients

Exclusion criteria

  1. with unstable hemodynamics
  2. with severe nausea or vomit which cannot be controlled by drugs
  3. allergic reaction to NutrenOpimum
  4. dysfunction of other organs
  5. with severe disease, such as infection, stroke, heart failure or stock
  6. other situation to be judged not adaptive to the study by investigators

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

374 participants in 2 patient groups

oral nutritional supplements
Experimental group
Description:
NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
Treatment:
Dietary Supplement: NutrenOpimum
standard diet
No Intervention group
Description:
The control group was given no additional postoperative nutritional supplementation (standard diet).

Trial contacts and locations

1

Loading...

Central trial contact

Runcong Nie, Ph.D.; Zhiwei Zhou, Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems